002728 Teyi Pharmaceutical Group
- 7.65
- +0.11+1.46%
Teyi Pharmaceutical Group News
Teyi Pharmaceutical Group (002728.SZ) has repurchased 1.18% of the shares.
On July 16th, Gelonhui reported that Teyi Pharmaceutical Group (002728.SZ) repurchased 6,005,260 shares of the company through the Shenzhen Stock Exchange trading system using centralized bidding trading method as of July 16, 2024, accounting for 1.18% of the total share capital. The highest repurchase price was 8.03 yuan/share and the lowest was 7.22 yuan/share. The total amount paid was RMB 44.2134 million (excluding related transaction fees).
Teyi Pharmaceutical Group: 2024 Interim Performance Forecast
Teyi Pharmaceutical Group (002728.SZ): Net income is expected to decrease by 97.90%-98.49% in the first half of the year.
On July 8, Gelunhui reported that Teyi Pharmaceutical Group (002728.SZ) announced the performance forecast for the first half of 2024. The net income attributable to shareholders of the listed company during the reporting period was RMB 2.3 million to RMB 3.2 million, down 98.49% to 97.90% from the same period last year. The net income after deducting non-recurring gains and losses was RMB 1.8 million to RMB 2.7 million, down 98.80% to 98.21% from the same period last year. The basic earning per share was RMB 0.005/share to RMB 0.006/share. During this reporting period, the company had a marketing organizational change, optimizing and adjusting the original organizational structure and marketing channels. Communication
Teyi Pharmaceutical Group (002728.SZ) bought back 258,000 shares for the first time, involving 2.03696 million yuan.
On June 24th, Gelunhui reported that Teyi Pharmaceutical Group (002728.SZ) announced its first share buyback through a centralized bidding transaction on the Shenzhen Stock Exchange trading system on June 24, 2024. The company repurchased 258,000 shares, accounting for 0.05% of the company's current total share capital. The highest price of the repurchase transaction was 7.91 yuan/share, the lowest price was 7.88 yuan/share, and the total amount paid was RMB 2.03696 million (excluding relevant transaction fees).
Teyi Pharmaceutical to Buy Back Up to 120 Million Yuan Shares; Shares Up 3%
Teyi Pharmaceutical Group (SHE:002728) plans to repurchase shares worth between 70 million yuan and 120 million yuan, the company said in a Wednesday disclosure on the Shenzhen Stock Exchange. The Chi
Teyi Pharmaceutical Group (002728.SZ) plans to spend 70-120 million yuan to repurchase company shares.
On June 11th, Gelonhui reported that Teyi Pharmaceutical Group (002728.SZ) plans to repurchase the company's issued common stock (A shares) for stock-based incentives or employee stock ownership plans. The total amount of repurchase funds is not less than RMB 70 million (inclusive) and not more than RMB 120 million (inclusive). The repurchase price is no more than RMB 12.96/share (inclusive). Based on the upper limit of the repurchase price of RMB 12.96/share, it is estimated that the range of the minimum and maximum repurchase quantity is about 5,401,234 shares to 9,259,259 shares, which account for the total share capital of the company.
Investors Aren't Entirely Convinced By Teyi Pharmaceutical Group Co.,Ltd's (SZSE:002728) Earnings
With a price-to-earnings (or "P/E") ratio of 26.1x Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) may be sending bullish signals at the moment, given that almost half of all companies in China have P
Teyi Pharmaceutical (002728.SZ): No related business has been carried out in the biological manufacturing industry
Gelonghui, May 21丨Teyi Pharmaceutical (002728.SZ) said on the investor interactive platform that the company has not yet carried out related business in the biological manufacturing industry. In terms of drug innovation research, the company continues to carry out two-way research and development of proprietary Chinese medicines and chemical drugs. In terms of proprietary Chinese medicine: Through clinical research or real-world research, specialty proprietary Chinese medicine products are developed twice to promote quality improvement through innovation, enhance the influence of “special” brands, and thereby enhance the market competitiveness of products; in terms of chemicals: mainly carrying out integrated innovative research on “active drugs+formulations” to conduct cutting-edge research on drugs for the treatment of major diseases
Teyi Pharmaceutical (002728.SZ): The company has not yet carried out any business related to synthetic organisms
Gelonghui, May 9 | Teyi Pharmaceutical (002728.SZ) said on the investor interactive platform that the company has not yet carried out any business related to synthetic organisms.
Teyi Pharmaceutical (002728.SZ): The company's inventory mainly includes raw materials, in-process products, finished products and low-value consumables
Gelonghui, May 9丨Teyi Pharmaceutical (002728.SZ) said on the investor interactive platform that the company's inventory mainly includes raw materials, in-process products, finished products, and low-value consumables. In terms of procurement, the company generally formulates raw material procurement plans based on market demand and raw material supply and demand, and implements economical batch purchases to control procurement costs, thereby reducing the company's operating costs. Furthermore, due to the gradual increase in the company's sales share and variety of proprietary Chinese medicinal products, the Chinese herbal medicines that the company needs to reserve have also increased accordingly. All of these will result in an increase in the company's material inventory. In terms of product inventory, the company will comprehensively consider market environment factors
Special Pharmaceutical (002728.SZ): One of the Chinese herbal medicines used in cough medicine tablets is simply an extract extracted from poppy shell. Poppy shell is a nationally controlled medicinal herb, priced by the National Development and Reform Co
Gelonghui, April 24 | Teyi Pharmaceutical (002728.SZ) said on the investor interactive platform that one of the Chinese herbal medicines used in the company's cough medicine is simply an extract extracted from poppy shells. Poppy shell is a nationally controlled medicinal herb, and the price is set by the National Development and Reform Commission. In addition, the other raw materials needed for cough medicine tablets, such as aster, orange red, bellflower, citrus aurantium, and 100 parts, are all common Chinese herbal medicines on the market. The market supply is large, and there is no supply pressure. In addition, the company is equipped with a special warehouse for Chinese herbal medicines, so the company can make sufficient safe reserves according to subsequent market needs. Judging from the current level of consumption of Cough Remedies, Cough Remedies every day
Teyi Pharmaceutical (002728.SZ): The company holds approvals for drugs such as Qianbai rhinitis tablets, etc., and is currently not producing
On April 24, Gelonghui Pharmaceutical (002728.SZ) said on the investor interactive platform that the company holds pharmaceutical approvals for ketotifen fumarate tablets, chlorphenamine maleate tablets, nasal comfort tablets, and Qianbai rhinitis tablets, and are currently not producing them.
Teyi Pharmaceutical (002728.SZ): Net profit of 9.1546 million yuan in the first quarter decreased by 91.32% year on year
On April 19, Ge Longhui Pharmaceutical (002728.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 165 million yuan, down 45.88% year on year; net profit attributable to shareholders of listed companies was 9.1546 million yuan, down 91.32% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 8.924,600 yuan, down 91.51% year on year; basic earnings per share were 0.03 yuan.
We Wouldn't Be Too Quick To Buy Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) Before It Goes Ex-Dividend
Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) stock is about to trade ex-dividend in 4 days. The ex-dividend date is one business day before the record date, which is the cut-off date for sharehold
Zhitong A Share Sale Restriction and Release List | April 11
According to the Zhitong Finance App, the ban on restricted shares of 9 listed companies was lifted on April 11, with a total market value of about 4.454 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Sinoma International 600970, share incentives, 15.3612 million, Teyi Pharmaceutical 002728, original shareholder placement and listing 2014.65 million Xingyuan Material 300568 share incentives limited sale and circulation of 1,5309 million Huichuangda 300909 additional A-shares, corporate placement and listing of 1,50312 Wan Jiangyan Group 601065 shares restricted circulation before issuance
Teyi Pharmaceutical (002728.SZ): The ban on 2014.65 million restricted shares will be lifted on April 11
Gelonghui, April 8, 丨 Teyi Pharmaceutical (002728.SZ) announced an indicative announcement on the issuance of restricted shares to specific targets in 2023. The number of restricted shares lifted this time is 201465.14 million shares, accounting for 5.5235% of the company's total share capital at present. The current limited-sale stock listing circulation date is April 11, 2024 (Thursday).
Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) Surges 7.2%; Retail Investors Who Own 54% Shares Profited Along With Insiders
Key Insights The considerable ownership by retail investors in Teyi Pharmaceutical GroupLtd indicates that they collectively have a greater say in management and business strategy The top 25 shareho
Teyi Pharmaceutical (002728.SZ): Currently there is no planting base for Chinese herbal medicines
Gelonghui, March 22丨Teyi Pharmaceutical (002728.SZ) said on the investor interactive platform that all Chinese herbal medicines required by the company to produce proprietary Chinese medicines are purchased from outside, and there is currently no Chinese herbal medicine cultivation base.
Teyi Pharmaceutical (002728.SZ): No research or plans on weight loss drugs
Gelonghui March 22丨Teyi Pharmaceutical (002728.SZ) said on the investor interactive platform that the company has no research or plans on diet pills yet.
Teyi Pharmaceutical GroupLtd (SZSE:002728) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) just reported some strong earnings, and the market reacted accordingly with a healthy uplift in the share price. However, our analysis suggests that sh
Analysis
Price Target
No Data
